Pharmaceutical companies publish a small portion of the results collected from drug trials; however most of the information collected is not made public. European regulatory bodies wish to increase the efficacy and safety of pharmaceuticals by requiring the companies to publish all of the data from their clinical trials. Regulators claim that increased transparency would allow independent researchers to verify that the results reported by these companies are accurate. Though some companies have agreed to share data, others have launched a campaign against the proposed regulations. Two groups, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), formed a strategy to mobilize patient advocacy groups to protest the regulation. The strategy was outlined in a memo, which was leaked to the public by an employee.
To read more click here.